Clinical Trials Logo

Clinical Trial Summary

The purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 plozasiran) in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of plozasiran or matching placebo administered subcutaneously. Participants who complete the randomized period will continue in a 2-year open-label extension period where all participants will receive plozasiran.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05089084
Study type Interventional
Source Arrowhead Pharmaceuticals
Contact
Status Active, not recruiting
Phase Phase 3
Start date January 11, 2022
Completion date April 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT03783377 - Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS) Phase 1
No longer available NCT03544060 - Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)